Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F12%3A%230000374" target="_blank" >RIV/00209805:_____/12:#0000374 - isvavai.cz</a>

Výsledek na webu

<a href="http://link.springer.com.proxy.mzk.cz/article/10.1007%2Fs12012-012-9164-0" target="_blank" >http://link.springer.com.proxy.mzk.cz/article/10.1007%2Fs12012-012-9164-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s12012-012-9164-0" target="_blank" >10.1007/s12012-012-9164-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review

Popis výsledku v původním jazyce

Cardiotoxicity associated with conventional cytostatics is a known phenomenon and is related to their general cytotoxic effects. This damage to the myocardium is usually irreversible. Despite the attempts to optimize safety profile of targeted anticancerdrugs during their development, evidence shows that these new treatment modalities also have cardiotoxic potential or may adversely affect vascular system. Over the last years, a significant number of these agents have been introduced in medical practice. Arterial hypertension, arrhythmias, left ventricular dysfunction and a heart failure are the most frequent cardiovascular adverse effects of targeted anticancer agents, but this toxicity seems to be reversible. To enable early interventions and to minimize these cardiovascular adverse effects, health care professionals have to be well-informed and familiar with the safety profiles of the drugs they administered, the patient's cardiovascular condition and co-morbidities, and they must

Název v anglickém jazyce

Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review

Popis výsledku anglicky

Cardiotoxicity associated with conventional cytostatics is a known phenomenon and is related to their general cytotoxic effects. This damage to the myocardium is usually irreversible. Despite the attempts to optimize safety profile of targeted anticancerdrugs during their development, evidence shows that these new treatment modalities also have cardiotoxic potential or may adversely affect vascular system. Over the last years, a significant number of these agents have been introduced in medical practice. Arterial hypertension, arrhythmias, left ventricular dysfunction and a heart failure are the most frequent cardiovascular adverse effects of targeted anticancer agents, but this toxicity seems to be reversible. To enable early interventions and to minimize these cardiovascular adverse effects, health care professionals have to be well-informed and familiar with the safety profiles of the drugs they administered, the patient's cardiovascular condition and co-morbidities, and they must

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cardiovascular toxicology

ISSN

1530-7905

e-ISSN

—

Svazek periodika

12

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

17

Strana od-do

191-207

Kód UT WoS článku

000306739100001

EID výsledku v databázi Scopus

—